Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 17 Sep 2018
At a glance
- Drugs Ambrisentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline
- 06 Sep 2018 Planned End Date changed from 31 Aug 2020 to 31 Jan 2020.
- 06 Sep 2018 Planned primary completion date changed from 31 Aug 2020 to 31 Jan 2020.
- 03 Jan 2018 New trial record